Von Hoff
About
In The Last Decade
Von Hoff
39 papers receiving 960 citations
Peers
Comparison fields: 5 of 90
- Oncology 540
- Molecular Biology 295
- Cardiology and Cardiovascular Medicine 221
- Pulmonary and Respiratory Medicine 171
- Pathology and Forensic Medicine 170
Countries citing papers authored by Von Hoff
This map shows the geographic impact of Von Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Von Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Von Hoff more than expected).
Fields of papers citing papers by Von Hoff
This network shows the impact of papers produced by Von Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Von Hoff. The network helps show where Von Hoff may publish in the future.
Co-authorship network of co-authors of Von Hoff
This figure shows the co-authorship network connecting the top 25 collaborators of Von Hoff. A scholar is included among the top collaborators of Von Hoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Von Hoff. Von Hoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Promising new agents for treatment of patients with colorectal cancer. | 10 |
| 2 | Gemcitabine: a case study for clinical benefit. | 4 |
| 3 | Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. | 11 |
| 4 | Implications of tumor cell heterogeneity for in vitro drug sensitivity testing. | 7 |
| 5 | Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic, and colorectal cancers. | 5 |
| 6 | Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study. | 9 |
| 7 | Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. | 23 |
| 8 | Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. | 31 |
| 9 | Bisantrene, an active drug in patients with advanced breast cancer. | 12 |
| 10 | Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. | 24 |
| 11 | Long-distance transportation of specimens for human tumor cloning. | 3 |
| 12 | Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys. | 11 |
| 13 | Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid. | 7 |
| 14 | In vitro evaluation of anticancer drugs with the human tumor stem cell assay. | 45 |
| 15 | Effective adjuvant treatments. A brief review of U.S. clinical trials. | 1 |
| 16 | Current trends and prospects in surgical adjuvant trials. | 2 |
| 17 | "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue. | 10 |
| 18 | Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. | 34 |
| 19 | Investigational chemotherapeutic agents in head and neck cancer. | 24 |
| 20 | Cytembena: an anticancer drug with an unique structure. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.